
## Tanya B Dorff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/473904/publications.pdf Version: 2024-02-01



TANVA R DODEE

#	Article	IF	CITATIONS
1	Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report. Journal of the National Cancer Institute, 2022, 114, 1036-1039.	6.3	74
2	Prostate Cancer Characteristics and Outcomes after Prostatectomy in Asian-American Men. Clinical Genitourinary Cancer, 2022, 20, 92-92.e6.	1.9	2
3	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 388-396.	3.9	15
4	Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer. Clinical Cancer Research, 2022, 28, 576-584.	7.0	26
5	Changes in perception of immunotherapy over time among patients with advanced genitourinary cancers Journal of Clinical Oncology, 2022, 40, 328-328.	1.6	0
6	Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine, 2022, 28, 704-712.	30.7	181
7	PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages. , 2022, 10, e004400.		16
8	Editor' summary: A paradigm shift in castration-resistant prostate cancer management. Prostate Cancer and Prostatic Diseases, 2022, 25, 601-603.	3.9	3
9	Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 61-68.	3.9	34
10	The Role of Diverse Populations in US Clinical Trials. Med, 2021, 2, 21-24.	4.4	14
11	High-throughput global transcriptional profiling to identify the STAT3 signaling pathway as a potential biomarker for immune checkpoint inhibitor resistance in metastatic/advanced urothelial carcinoma Journal of Clinical Oncology, 2021, 39, 474-474.	1.6	0
12	The effects of bright white light therapy on obese frailty in older men with prostate cancer on hormonal therapy: A pilot randomized control trial Journal of Clinical Oncology, 2021, 39, 75-75.	1.6	0
13	Wnt/ $\hat{I}^2$ -Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma. Cancers, 2021, 13, 889.	3.7	24
14	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 134-143.	4.9	299
15	Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens. Clinical Genitourinary Cancer, 2021, 19, 125-134.	1.9	4
16	Role of Ki-67, MRE11, and PD-L1 as Predictive Biomarkers for Recurrence Pattern in Muscle-invasive Bladder Cancer. Anticancer Research, 2021, 41, 3851-3857.	1.1	1
17	Hormonal manipulation in androgen signaling: a narrative review on using novel androgen therapy agents to optimize clinical outcomes and minimize side effects for prostate cancer patients. Translational Andrology and Urology, 2021, 10, 3199-3207.	1.4	6
18	Pre-conditioning modifies the TME to enhance solid tumor CAR TÂcell efficacy and endogenous protective immunity. Molecular Therapy, 2021, 29, 2335-2349.	8.2	51

TANYA B DORFF

#	Article	IF	CITATIONS
19	Salvage therapy for prostate cancer after radical prostatectomy. Nature Reviews Urology, 2021, 18, 643-668.	3.8	26
20	Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. , 2021, 9, e002931.		18
21	Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy. JCO Oncology Practice, 2021, , OP.21.00574.	2.9	1
22	25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 521-527.	1.6	3
23	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 83-93.	1.6	24
24	NCl–Clinical Trial Accrual in a Community Network Affiliated with a Designated Cancer Center. Journal of Clinical Medicine, 2020, 9, 1970.	2.4	4
25	Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 485-489.	1.0	2
26	Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. European Urology, 2020, 77, 614-627.	1.9	101
27	Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature. Clinical Genitourinary Cancer, 2020, 18, e473-e477.	1.9	1
28	Cancer transcriptomic profiling from rapidly enriched circulating tumor cells. International Journal of Cancer, 2020, 146, 2845-2854.	5.1	7
29	<i>CDK12</i> -Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. JCO Precision Oncology, 2020, 4, 382-392.	3.0	51
30	COVID-19 and androgen-targeted therapy for prostate cancer patients. Endocrine-Related Cancer, 2020, 27, R281-R292.	3.1	64
31	Defining Value in Metastatic Prostate Cancer: What Is the Cost of Living Longer and Better?. JCO Oncology Practice, 2020, 16, 53-54.	2.9	1
32	The Evolving Role of Prostate-Specific Membrane Antigen–Based Diagnostics and Therapeutics in Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 321-330.	3.8	33
33	Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clinical Genitourinary Cancer, 2019, 17, 241-247.e1.	1.9	11
34	Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy. , 2019, 7, 71.		21
35	Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 50-60.	0.8	21
36	Impact of timing of administration of bone supportive therapy on pain palliation from radium-223. Cancer Treatment and Research Communications, 2019, 18, 100114.	1.7	9

Tanya B Dorff

#	Article	IF	CITATIONS
37	Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 1-11.	1.6	11
38	Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). Clinical Genitourinary Cancer, 2018, 16, e11-e21.	1.9	9
39	Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients. Clinical Genitourinary Cancer, 2018, 16, 90-98.e1.	1.9	11
40	Bone-targeted therapies to reduce skeletal morbidity in prostate cancer. Asian Journal of Andrology, 2018, 20, 215.	1.6	14
41	Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. Journal of Clinical Medicine, 2018, 7, 156.	2.4	10
42	Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGIâ€110) in Hepatocellular Carcinoma. Hepatology, 2018, 68, 1412-1428.	7.3	48
43	Low-dimensional dynamical characterization of human performance of cancer patients using motion data. Clinical Biomechanics, 2018, 56, 61-69.	1.2	5
44	Phase I study of stereotactic body radiotherapy following radical prostatectomy Journal of Clinical Oncology, 2018, 36, TPS158-TPS158.	1.6	1
45	Multi-parametric liquid biopsy analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and cell-free RNA (cfRNA) in metastatic castrate resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2018, 36, 274-274.	1.6	3
46	High dose interleukin-2 and response in 944 patients with metastatic renal cell cancer (RCC): Data from the PROCLAIM registry Journal of Clinical Oncology, 2018, 36, 624-624.	1.6	1
47	Novel method for rapid enrichment of high purity circulating tumor cells (CTCs) for prostate cancer (PCa) gene expression profiling Journal of Clinical Oncology, 2018, 36, 271-271.	1.6	0
48	Immune-related adverse events (irAE) in GU cancer patients receiving immune checkpoint inhibitors Journal of Clinical Oncology, 2018, 36, 422-422.	1.6	0
49	Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Science Translational Medicine, 2017, 9, .	12.4	363
50	Robotic salvage retroperitoneal and pelvic lymph node dissection for â€~nodeâ€only' recurrent prostate cancer: technique and initial series. BJU International, 2017, 120, 401-408.	2.5	27
51	Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer, 2017, 123, 4566-4573.	4.1	37
52	A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 742-749.	1.9	21
53	Chemotherapy for oligometastatic prostate cancer. Current Opinion in Urology, 2017, 27, 553-558.	1.8	4
54	A pilot randomised controlled trial of a periodised resistance training and protein supplementation in prostate cancer survivors on androgen deprivation therapy, BMI Open, 2017, 7, e016910	1.9	14

#	Article	IF	CITATIONS
55	Current Management Strategy for Penile Cancer and Future Directions. Current Oncology Reports, 2017, 19, 54.	4.0	10
56	Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG) Tj ETQq0 0 0	) rg <b>B₹</b> /Ov	erlasck 10 Tf 5
57	Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG) Tj ETQq1 1 C	).78.4314	rg <b>B</b> T /Overloc
58	Impact of resistance exercise on metabolic syndrome (MetS) parameters in men receiving androgen deprivation therapy (ADT) for prostate cancer Journal of Clinical Oncology, 2017, 35, 223-223.	1.6	1
59	A phase II trial of zoptarelin doxorubicin in castration- and taxane-resistant prostate cancer Journal of Clinical Oncology, 2017, 35, 210-210.	1.6	1
60	Comprehensive genomic profiling of urethral cancer to reveal distinctive features compared to bladder cancer Journal of Clinical Oncology, 2017, 35, 429-429.	1.6	0
61	Randomized phase II trial of abiraterone +/- dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2017, 35, 167-167.	1.6	1
62	Adjuvant androgen deprivation (AD) +/- mitoxantrone + prednisone (MP) in patients with high-risk prostate cancer (PC) post radical prostatectomy (RP): Phase III intergroup trial S9921 Journal of Clinical Oncology, 2017, 35, 5019-5019.	1.6	0
63	Impact of timing of administration of bone supportive therapy on pain palliation from radium-223 Journal of Clinical Oncology, 2017, 35, 5023-5023.	1.6	1
64	Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. Clinical Advances in Hematology and Oncology, 2017, 15, 466-477.	0.3	3
65	Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. Clinical Advances in Hematology and Oncology, 2017, 15, 543-551.	0.3	6
66	Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer. Clinical Genitourinary Cancer, 2016, 14, 450-456.e1.	1.9	6
67	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. Journal of Clinical Oncology, 2016, 34, 2478-2483.	1.6	31
68	Adjuvant chemotherapy for bladder cancer: A detailed characterization of factors precluding utilization Journal of Clinical Oncology, 2016, 34, e16001-e16001.	1.6	0
69	Outcomes in neuroendocrine bladder cancer treated with radical cystectomy Journal of Clinical Oncology, 2016, 34, e16004-e16004.	1.6	0
70	Immunomodulation by HDAC inhibition: Results from a phase II study with entinostat and high-dose interleukin 2 in metastatic renal cell carcinoma patients (CTEP#7870) Journal of Clinical Oncology, 2016, 34, 4560-4560.	1.6	0
71	Relapsed and refractory germ cell tumors: Finessing the rough end of a beautiful story. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 341-342.	1.6	1
72	A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. Cell Metabolism, 2015, 22, 86-99.	16.2	635

TANYA B DORFF

#	Article	IF	CITATIONS
73	Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors. Urologic Clinics of North America, 2015, 42, 347-357.	1.8	4
74	Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer. Clinical Cancer Research, 2014, 20, 6277-6283.	7.0	39
75	Novel tyrosine kinase inhibitors for renal cell carcinoma. Expert Review of Clinical Pharmacology, 2014, 7, 67-73.	3.1	9
76	Durable Complete Remission From Castration-Resistant Prostate Cancer With Sipuleucel-T After Estrogen Withdrawal. Clinical Genitourinary Cancer, 2014, 12, e55-e58.	1.9	1
77	Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: A critical analysis of 1,994 patients. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 52.e1-52.e9.	1.6	55
78	Epidermal Growth Factor Receptor-targeted Therapy in Squamous Cell Carcinoma of the Penis: A Report of 3 Cases. Urology, 2014, 83, 159-166.	1.0	30
79	Clinicopathologic Characteristics and OutcomesÂof Penile Cancer Treated at Tertiary Care Centers in the Western United States. Clinical Genitourinary Cancer, 2014, 12, 138-142.	1.9	15
80	Prolonged Fasting Reduces IGF-1/PKA to Promote Hematopoietic-Stem-Cell-Based Regeneration and Reverse Immunosuppression. Cell Stem Cell, 2014, 14, 810-823.	11.1	369
81	Baseline <sup>18</sup> F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2013, 54, 1195-1201.	5.0	110
82	Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer. Current Opinion in Urology, 2013, 23, 366-371.	1.8	16
83	Changes in circulating tumor cells (CTC) and markers of inflammation after sipuleucel-T treatment Journal of Clinical Oncology, 2013, 31, 40-40.	1.6	1
84	Factors influencing postâ€recurrence survival in bladder cancer following radical cystectomy. BJU International, 2012, 109, 846-854.	2.5	101
85	A phase I trial of AEZS-108 (AN-152) in castration- and taxane-resistant prostate cancer Journal of Clinical Oncology, 2012, 30, 60-60.	1.6	0
86	Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study. Journal of Clinical Oncology, 2011, 29, 2040-2045.	1.6	94
87	Use of Testosterone Replacement Therapy in Patients with Prostate Cancer. Current Urology Reports, 2011, 12, 223-228.	2.2	8
88	The Epothilones: New Therapeutic Agents for Castration-Resistant Prostate Cancer. Oncologist, 2011, 16, 1349-1358.	3.7	18
89	Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU International, 2010, 105, 1397-1401.	2.5	58
90	Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2010, 16, 3028-3034.	7.0	187

TANYA B DORFF

#	Article	IF	CITATIONS
91	Cabazitaxel in prostate cancer: stretching a string. Lancet, The, 2010, 376, 1119-1120.	13.7	13
92	Review: Targeted therapy in renal cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 183-205.	3.2	16
93	Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. World Journal of Urology, 2009, 27, 39-44.	2.2	11
94	Evolving treatment paradigms for locally advanced and metastatic prostate cancer. Expert Review of Anticancer Therapy, 2006, 6, 1639-1651.	2.4	3
95	Ethnic differences in neuroendocrine cell expression in normal human prostatic tissue. Urology, 2005, 65, 1008-1012.	1.0	11